Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.

M. Feldmesser, A. Casadevall

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cryptococcus neoformans is an encapsulated fungus that causes meningoencephalitis in 5-10% of patients with AIDS. While the immune response that controls infection is predominantly cell-mediated, Ab-mediated immunity is being studied for therapeutic use. mAbs to glucuronoxylomannan (GXM), the predominant constituent of the polysaccharide capsule are protective in a variety of murine infection models. However, the mechanism of Ab action in this infection is unknown. We review the literature on the effect of Ab in cryptococcal infection and potential mechanisms of action. The mechanism is likely multifactorial, involving enhancement at several branches of the immune response, including opsonization, antigen presentation and altered effector cell function. Removal of the toxic and immunosuppressive effects of GXM may be an important component of the mechanism of Ab action. Changes in pathology in response to monoclonal antibody (mAb) administration suggest that alterations in cytokine production may mediate mAb effects. In summary, specific Ab can modulate the course of cryptococcal infection to the benefit or detriment of the host, but significant questions remain concerning the mechanism of action and the relative importance of antibody-mediated immunity in normal and immunocompromised hosts.

Original languageEnglish (US)
JournalFrontiers in Bioscience
Volume3
StatePublished - 1998

Fingerprint

Cryptococcus neoformans
Polysaccharides
Monoclonal Antibodies
Antibodies
Poisons
Pathology
Immunosuppressive Agents
Infection
Fungi
Capsules
Immunity
Cytokines
Antigens
Meningoencephalitis
Antigen Presentation
Immunocompromised Host
Therapeutic Uses
Infection Control
Action Potentials
Acquired Immunodeficiency Syndrome

Cite this

Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection. / Feldmesser, M.; Casadevall, A.

In: Frontiers in Bioscience, Vol. 3, 1998.

Research output: Contribution to journalArticle

@article{4981aad9a0d8479abfaa93303fb98b32,
title = "Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.",
abstract = "Cryptococcus neoformans is an encapsulated fungus that causes meningoencephalitis in 5-10{\%} of patients with AIDS. While the immune response that controls infection is predominantly cell-mediated, Ab-mediated immunity is being studied for therapeutic use. mAbs to glucuronoxylomannan (GXM), the predominant constituent of the polysaccharide capsule are protective in a variety of murine infection models. However, the mechanism of Ab action in this infection is unknown. We review the literature on the effect of Ab in cryptococcal infection and potential mechanisms of action. The mechanism is likely multifactorial, involving enhancement at several branches of the immune response, including opsonization, antigen presentation and altered effector cell function. Removal of the toxic and immunosuppressive effects of GXM may be an important component of the mechanism of Ab action. Changes in pathology in response to monoclonal antibody (mAb) administration suggest that alterations in cytokine production may mediate mAb effects. In summary, specific Ab can modulate the course of cryptococcal infection to the benefit or detriment of the host, but significant questions remain concerning the mechanism of action and the relative importance of antibody-mediated immunity in normal and immunocompromised hosts.",
author = "M. Feldmesser and A. Casadevall",
year = "1998",
language = "English (US)",
volume = "3",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.

AU - Feldmesser, M.

AU - Casadevall, A.

PY - 1998

Y1 - 1998

N2 - Cryptococcus neoformans is an encapsulated fungus that causes meningoencephalitis in 5-10% of patients with AIDS. While the immune response that controls infection is predominantly cell-mediated, Ab-mediated immunity is being studied for therapeutic use. mAbs to glucuronoxylomannan (GXM), the predominant constituent of the polysaccharide capsule are protective in a variety of murine infection models. However, the mechanism of Ab action in this infection is unknown. We review the literature on the effect of Ab in cryptococcal infection and potential mechanisms of action. The mechanism is likely multifactorial, involving enhancement at several branches of the immune response, including opsonization, antigen presentation and altered effector cell function. Removal of the toxic and immunosuppressive effects of GXM may be an important component of the mechanism of Ab action. Changes in pathology in response to monoclonal antibody (mAb) administration suggest that alterations in cytokine production may mediate mAb effects. In summary, specific Ab can modulate the course of cryptococcal infection to the benefit or detriment of the host, but significant questions remain concerning the mechanism of action and the relative importance of antibody-mediated immunity in normal and immunocompromised hosts.

AB - Cryptococcus neoformans is an encapsulated fungus that causes meningoencephalitis in 5-10% of patients with AIDS. While the immune response that controls infection is predominantly cell-mediated, Ab-mediated immunity is being studied for therapeutic use. mAbs to glucuronoxylomannan (GXM), the predominant constituent of the polysaccharide capsule are protective in a variety of murine infection models. However, the mechanism of Ab action in this infection is unknown. We review the literature on the effect of Ab in cryptococcal infection and potential mechanisms of action. The mechanism is likely multifactorial, involving enhancement at several branches of the immune response, including opsonization, antigen presentation and altered effector cell function. Removal of the toxic and immunosuppressive effects of GXM may be an important component of the mechanism of Ab action. Changes in pathology in response to monoclonal antibody (mAb) administration suggest that alterations in cytokine production may mediate mAb effects. In summary, specific Ab can modulate the course of cryptococcal infection to the benefit or detriment of the host, but significant questions remain concerning the mechanism of action and the relative importance of antibody-mediated immunity in normal and immunocompromised hosts.

UR - http://www.scopus.com/inward/record.url?scp=0001385204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001385204&partnerID=8YFLogxK

M3 - Article

C2 - 9445465

AN - SCOPUS:0001385204

VL - 3

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -